2025 Thai guideline for the diagnosis and management of atrial fibrillation

Ngarmukos, Tachapong; Methavigul, Komsing; Rungpradubvong, Voravut; Apiyasawat, Sirin; Wongcharoen, Wanwarang; Pumprueg, Satchana; Boonyapisit, Warangkana; Suwannagool, Arisara; Chantrarat, Thoranis; Makarawate, Pattarapong; Wisaratapong, Treechada; Chintanavilas, Kumpol; Jiampo, Panyapat; Krittayaphong, Rungroj

doi:10.2478/abm-2025-0028

Abstract

Background

The Thai Cardiac Electrophysiology Club, part of the Heart Association of Thailand under the Royal Patronage of His Majesty the King, published a Clinical Practice Guideline for the Management of Patients with Atrial Fibrillation (AF) in 2012. The availability of new evidence indicates a significant need for the updating of the existing clinical practice guideline.

Objective

To serve as guidelines on the diagnosis and management of Thai patients with AF.

Methods

Meetings were conducted from September 2024 to March 2025, including a public hearing that engaged various stakeholders. The final Thai version received approval in February 2025, while the English translation was completed in April 2025.

Results

AF is highly prevalent. The diagnosis is crucial to detect those who need treatment for the prevention of complication. Holistic management focused on stroke prevention, symptom management, and management of cardiovascular risk factors; and comorbidity is the key success factor to maintain a good quality of life. Emerging evidence regarding newer classes of anticoagulant indicates that these treatments are effective and safe for stroke prevention. Newer catheter ablation technology has been developed and provides a better success rate and lower rate of complication. The newer stroke risk prediction CHA₂DS₂-VA Score is recommended for the Thai population due to its simplicity.

Conclusion

The 2025 updated AF clinical practice guidelines establish a framework, provide recommendations, and serve as a comprehensive resource for the contemporary diagnosis and management of AF in the Thai population, with the goal of preventing complications.

References

Joglar JA, Chung MK, Armbruster AL, Benjamin EJ, Chyou JY, Cronin EM, et al. 2023 ACC/AHA/ACCP/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2024; 149:e1–156. doi: 10.1161/CIR.0000000000001193
Open DOI Search in Google Scholar Back to article
Van Gelder IC, Rienstra M, Bunting KV, Casado-Arroyo R, Caso V, Crijns HJGM, et al. 2024 ESC guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2024; 45:3314–414.
Search in Google Scholar Back to article
Hobbs FD, Fitzmaurice DA, Mant J, Murray E, Jowett S, Bryan S, et al. A randomised controlled trial and cost-effectiveness study of systematic screening (targeted and total population screening) versus routine practice for the detection of atrial fibrillation in people aged 65 and over. The SAFE study. Health Technol Assess. 2005; 9:iii-iv, ix-x, 1–74. doi: 10.3310/hta9400
Open DOI Search in Google Scholar Back to article
Suwanwela NC, Chutinet A, Autjimanon H, Ounahachok T, Decha-Umphai C, Chockchai S, et al. Atrial fibrillation prevalence and risk profile from novel community-based screening in Thailand: a prospective multi-centre study. Int J Cardiol Heart Vasc. 2021; 32:100709. doi: 10.1016/j.ijcha.2020.100709
Open DOI Search in Google Scholar Back to article
Phrommintikul A, Detnuntarat P, Prasertwitayakij N, Wongcharoen W. Prevalence of atrial fibrillation in Thai elderly. J Geriatr Cardiol. 2016; 13:270–3.
Search in Google Scholar Back to article
Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, et al. 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the task force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021; 42:373–498.
Search in Google Scholar Back to article
Sanna T, Diener HC, Passman RS, Di Lazzaro V, Bernstein RA, Morillo CA, et al. Cryptogenic stroke and underlying atrial fibrillation. N Engl J Med. 2014; 370:2478–86.
Search in Google Scholar Back to article
Sagris D, Harrison SL, Buckley BJR, Ntaios G, Lip GYH. Long-term cardiac monitoring after embolic stroke of undetermined source: search longer, look harder. Am J Med. 2022; 135:e311-e317. doi: 10.1016/j. amjmed.2022.04.030
Open DOI Search in Google Scholar Back to article
Liantinioti C, Palaiodimou L, Tympas K, Parissis J, Theodorou A, Ikonomidis I, et al. Potential utility of neurosonology in paroxysmal atrial fibrillation detection in patients with cryptogenic stroke. J Clin Med. 2019; 8:2022. doi: 10.3390/jcm8112002
Open DOI Search in Google Scholar Back to article
Favilla CG, Ingala E, Jara J, Fessler E, Cucchiara B, Messé SR, et al. Predictors of finding occult atrial fibrillation after cryptogenic stroke. Stroke. 2015; 46:1210–5.
Search in Google Scholar Back to article
Grond M, Jauss M, Hamann G, Stark E, Veltkamp R, Nabavi D, et al. Improved detection of silent atrial fibrillation using 72-hour Holter ECG in patients with ischemic stroke: a prospective multicenter cohort study. Stroke. 2013; 44:3357–64.
Search in Google Scholar Back to article
Barrett PM, Komatireddy R, Haaser S, Topol S, Sheard J, Encinas J, et al. Comparison of 24-hour Holter monitoring with 14-day novel adhesive patch electrocardiographic monitoring. Am J Med. 2014; 127:95.e11–97. doi: 10.1016/j.amjmed.2013.10.003
Open DOI Search in Google Scholar Back to article
Turakhia MP, Ullal AJ, Hoang DD, Than CT, Miller JD, Friday KJ, et al. Feasibility of extended ambulatory electrocardiogram monitoring to identify silent atrial fibrillation in high-risk patients: the Screening Study for Undiagnosed Atrial Fibrillation (STUDY-AF). Clin Cardiol. 2015; 38:285–92.
Search in Google Scholar Back to article
Steinhubl SR, Waalen J, Edwards AM, Ariniello LM, Mehta RR, Ebner GS, et al. Effect of a home-based wearable continuous ECG monitoring patch on detection of undiagnosed atrial fibrillation: the mSToPS randomized clinical trial. JAMA. 2018; 320:146–55.
Search in Google Scholar Back to article
Rizos T, Güntner J, Jenetzky E, Marquardt L, Reichardt C, Becker R, et al. Continuous stroke unit electrocardiographic monitoring versus 24-hour Holter electrocardiography for detection of paroxysmal atrial fibrillation after stroke. Stroke. 2012; 43:2689–94.
Search in Google Scholar Back to article
Musat DL, Milstein N, Mittal S. Implantable loop recorders for cryptogenic stroke (plus real-world atrial fibrillation detection rate with implantable loop recorders). Card Electrophysiol Clin. 2018; 10:111–8.
Search in Google Scholar Back to article
Nölker G, Mayer J, Boldt LH, Seidl K, VAN Driel V, Massa T, et al. Performance of an implantable cardiac monitor to detect atrial fibrillation: results of the DETECT AF study. J Cardiovasc Electrophysiol. 2016; 27:1403–10.
Search in Google Scholar Back to article
Tieleman RG, Plantinga Y, Rinkes D, Bartels GL, Posma JL, Cator R, et al. Validation and clinical use of a novel diagnostic device for screening of atrial fibrillation. Europace. 2014; 16:1291–5.
Search in Google Scholar Back to article
Lubitz SA, Faranesh AZ, Atlas SJ, McManus DD, Singer DE, Pagoto S, et al. Rationale and design of a large population study to validate software for the assessment of atrial fibrillation from data acquired by a consumer tracker or smartwatch: the Fitbit heart study. Am Heart J. 2021; 238:16–26.
Search in Google Scholar Back to article
Perez MV, Mahaffey KW, Hedlin H, Rumsfeld JS, Garcia A, Ferris T, et al. Large-scale assessment of a smartwatch to identify atrial fibrillation. N Engl J Med. 2019; 381:1909–17.
Search in Google Scholar Back to article
Tops LF, Schalij MJ, Bax JJ. Imaging and atrial fibrillation: the role of multimodality imaging in patient evaluation and management of atrial fibrillation. Eur Heart J. 2010; 31:542–51.
Search in Google Scholar Back to article
Roney CH, Sillett C, Whitaker J, Lemus JAS, Sim I, Kotadia I, et al. Applications of multimodality imaging for left atrial catheter ablation. Eur Heart J Cardiovasc Imaging. 2021; 23:31–41.
Search in Google Scholar Back to article
Troughton RW, Asher CR, Klein AL. The role of echocardiography in atrial fibrillation and cardioversion. Heart. 2003; 89:1447–54.
Search in Google Scholar Back to article
Krittayaphong R, Chichareon P, Methavigul K, Treewaree S, Lip GYH. Relation of changes in ABC pathway compliance status to clinical outcomes in patients with atrial fibrillation: a report from the COOL-AF registry. Eur Heart J Qual Care Clin Outcomes. 2024; 11:239–48.
Search in Google Scholar Back to article
Krittayaphong R, Treewaree S, Lip GYH. Components of the atrial fibrillation better care pathway for holistic care of patients with atrial fibrillation: a win ratio analysis from the COOL-AF registry. Europace. 2024; 26:euae237. doi: 10.1093/europace/euae237
Open DOI Search in Google Scholar Back to article
Chao TF, Joung B, Takahashi Y, Lim TW, Choi EK, Chan YH, et al. 2021 focused update of the 2017 consensus guidelines of the Asia Pacific Heart Rhythm Society (APHRS) on stroke prevention in atrial fibrillation. J Arrhythm. 2021; 37:1389–426.
Search in Google Scholar Back to article
Wolf PA, Dawber TR, Thomas HE Jr, Kannel WB. Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: the Framingham study. Neurology. 1978; 28:973–7.
Search in Google Scholar Back to article
Wang KL, Lip GY, Lin SJ, Chiang CE. Non-vitamin K antagonist oral anticoagulants for stroke prevention in Asian patients with nonvalvular atrial fibrillation: meta-analysis. Stroke. 2015; 46:2555–61.
Search in Google Scholar Back to article
Friberg L, Rosenqvist M, Lip GY. Net clinical benefit of warfarin in patients with atrial fibrillation: a report from the Swedish atrial fibrillation cohort study. Circulation. 2012; 125:2298–307.
Search in Google Scholar Back to article
Lip GY, Skjoth F, Nielsen PB, Larsen TB. Non-valvular atrial fibrillation patients with none or one additional risk factor of the CHA₂DS₂-VASc score. A comprehensive net clinical benefit analysis for warfarin, aspirin, or no therapy. Thromb Haemost. 2015; 114:826–34.
Search in Google Scholar Back to article
Chao TF, Lip GYH, Liu CJ, Lin YJ, Chang SL, Lo LW, et al. Relationship of aging and incident comorbidities to stroke risk in patients with atrial fibrillation. J Am Coll Cardiol. 2018; 71:122–32.
Search in Google Scholar Back to article
Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation. Chest. 2010; 137:263–72.
Search in Google Scholar Back to article
Teppo K, Lip GYH, Airaksinen KEJ, Halminen O, Haukka J, Putaala J, et al. Comparing CHA₂DS₂-VA and CHA₂DS₂-VASc scores for stroke risk stratification in patients with atrial fibrillation: a temporal trends analysis from the retrospective Finnish AntiCoagulation in Atrial Fibrillation (FinACAF) cohort. Lancet Reg Health Eur. 2024; 43:100967. doi: 10.1016/j. lanepe.2024.100967
Open DOI Search in Google Scholar Back to article
Krittayaphong R, Apiyasawat S, Methavigul K, Komoltri C, Lip GYH. Prediction of ischemic stroke by the CHA₂DS₂-VA score in an Asian population: a report from the prospective nationwide COOL-AF registry. Heart Rhythm. 2025. doi: 10.1016/j. hrthm.2025.04.062
Open DOI Search in Google Scholar Back to article
Krittayaphong R, Chichareon P, Komoltri C, Kornbongkotmas S, Yindeengam A, Lip GYH. Low body weight increases the risk of ischemic stroke and major bleeding in atrial fibrillation: the COOL-AF registry. J Clin Med. 2020; 9:2713. doi: 10.3390/jcm9092713
Open DOI Search in Google Scholar Back to article
Jung H, Yang PS, Sung JH, Jang E, Yu HT, Kim TH, et al. Hypertrophic cardiomyopathy in patients with atrial fibrillation: prevalence and associated stroke risks in a nationwide cohort study. Thromb Haemost. 2019; 119:285–93.
Search in Google Scholar Back to article
Eikelboom JW, Connolly SJ, Brueckmann M, Granger CB, Kappetein AP, Mack MJ, et al. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med. 2013; 369:1206–14.
Search in Google Scholar Back to article
Vadmann H, Nielsen PB, Hjortshøj SP, Riahi S, Rasmussen LH, Lip GY, et al. Atrial flutter and thromboembolic risk: a systematic review. Heart. 2015; 101:1446–55.
Search in Google Scholar Back to article
Lopes RD, Granger CB, Wojdyla DM, McIntyre WF, Alings M, Mani T, et al. Apixaban vs aspirin according to CHA₂DS₂-VASc score in subclinical atrial fibrillation: insights from ARTESiA. J Am Coll Cardiol. 2024; 84:354–64.
Search in Google Scholar Back to article
Van Gelder IC, Healey JS, Crijns HJGM, Wang J, Hohnloser SH, Gold MR, et al. Duration of device-detected subclinical atrial fibrillation and occurrence of stroke in ASSERT. Eur Heart J. 2017; 38:1339–44.
Search in Google Scholar Back to article
Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009; 361:1139–51.
Search in Google Scholar Back to article
Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011; 365:883–91.
Search in Google Scholar Back to article
Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011; 365:981–92.
Search in Google Scholar Back to article
Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013; 369:2093–104.
Search in Google Scholar Back to article
Connolly SJ, Karthikeyan G, Ntsekhe M, Haileamlak A, El Sayed A, El Ghamrawy A, et al. Rivaroxaban in rheumatic heart disease-associated atrial fibrillation. N Engl J Med. 2022; 387:978–88.
Search in Google Scholar Back to article
Krittayaphong R, Permsuwan U. Employing real-world evidence for the economic evaluation of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation in Thailand. Appl Health Econ Health Policy. 2024; 22:725–34.
Search in Google Scholar Back to article
Treewaree S, Lip GYH, Krittayaphong R. Non-vitamin K antagonist oral anticoagulant, warfarin, and ABC pathway adherence on hierarchical outcomes: win ratio analysis of the COOL-AF registry. Thromb Haemost. 2024; 124:69–79.
Search in Google Scholar Back to article
Krittayaphong R, Pumprueg S, Yindeengam A, Lip GYH. Number needed to treat for net clinical benefit of oral anticoagulants in Asian patients with atrial fibrillation. J Arrhythm. 2025; 41:e70023. doi: 10.1002/joa3.70023
Open DOI Search in Google Scholar Back to article
Krittayaphong R, Chantrarat T, Rojjarekampai R, Jittham P, Sairat P, Lip GYH. Poor time in therapeutic range control is associated with adverse clinical outcomes in patients with non-valvular atrial fibrillation: a report from the nationwide COOL-AF registry. J Clin Med. 2020; 9:1698. doi: 10.3390/jcm9061698
Open DOI Search in Google Scholar Back to article
Krittayaphong R, Kunjara-Na-Ayudhya R, Ngamjanyaporn P, Boonyaratavej S, Komoltri C, Yindeengam A, et al. Optimal INR level in elderly and non-elderly patients with atrial fibrillation receiving warfarin: a report from the COOL-AF nationwide registry in Thailand. J Geriatr Cardiol. 2020; 17:612–20.
Search in Google Scholar Back to article
Fawzy AM, Lip GYH. Pharmacokinetics and pharmacodynamics of oral anticoagulants used in atrial fibrillation. Expert Opin Drug Metab Toxicol. 2019; 15:381–98.
Search in Google Scholar Back to article
Ujjin A, Wongcharoen W, Suwanagool A, Chai-Adisaksopha C. Optimal strategies to select warfarin dose for Thai patients with atrial fibrillation. J Clin Med. 2024; 13:2675. doi: 10.3390/jcm13092675
Open DOI Search in Google Scholar Back to article
Singkham N, Phrommintikul A, Pacharasupa P, Norasetthada L, Gunaparn S, Prasertwitayakij N, et al. Population pharmacokinetics and dose optimization based on renal function of rivaroxaban in Thai patients with non-valvular atrial fibrillation. Pharmaceutics. 2022; 14:1744. doi: 10.3390/pharmaceutics14081744
Open DOI Search in Google Scholar Back to article
Chong DT, Andreotti F, Verhamme P, Dalal J, Uaprasert N, Wang CC, et al. Direct oral anticoagulants in Asian patients with atrial fibrillation: consensus recommendations by the Asian Pacific Society of Cardiology on strategies for thrombotic and bleeding risk management. Eur Cardiol. 2021; 16:e23. doi: 10.15420/ecr.2020.43
Open DOI Search in Google Scholar Back to article
Rosendaal FR, Cannegieter SC, van der Meer FJ, Briet E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost. 1993; 69:236–9.
Search in Google Scholar Back to article
Miyamoto S, Ikeda T, Ogawa S, Kitazono T, Nakagawara J, Minematsu K, et al. Clinical risk factors of thromboembolic and major bleeding events for patients with atrial fibrillation treated with rivaroxaban in Japan. J Stroke Cerebrovasc Dis. 2020; 29:104584. doi: 10.1016/j.jstrokecerebrovasdis.2019.104584
Open DOI Search in Google Scholar Back to article
Guo Y, Zhu H, Chen Y, Lip GYH. Comparing bleeding risk assessment focused on modifiable risk factors only versus validated bleeding risk scores in atrial fibrillation. Am J Med. 2018; 131:185–92.
Search in Google Scholar Back to article
Nee R, Doppenschmidt D, Donovan DJ, Andrews TC. Intravenous versus subcutaneous vitamin K1 in reversing excessive oral anticoagulation. Am J Cardiol. 1999; 83:286–8, A6–7. doi: 10.1016/S0002-9149(98)00842-X
Open DOI Search in Google Scholar Back to article
Pollack CV Jr, Reilly PA, van Ryn J, Eikelboom JW, Glund S, Bernstein RA, et al. Idarucizumab for dabigatran reversal – full cohort analysis. N Engl J Med. 2017; 377:431–41.
Search in Google Scholar Back to article
Connolly SJ, Crowther M, Eikelboom JW, Gibson CM, Curnutte JT, Lawrence JH, et al. Full study report of andexanet alfa for bleeding associated with factor Xa inhibitors. N Engl J Med. 2019; 380:1326–35.
Search in Google Scholar Back to article
Chai-Adisaksopha C, Hillis C, Siegal DM, Movilla R, Heddle N, Iorio A, et al. Prothrombin complex concentrates versus fresh frozen plasma for warfarin reversal. A systematic review and meta-analysis. Thromb Haemost. 2016; 116:879–90.
Search in Google Scholar Back to article
Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebocontrolled, crossover study in healthy subjects. Circulation. 2011; 124:1573–9.
Search in Google Scholar Back to article
Reddy VY, Doshi SK, Kar S, Gibson DN, Price MJ, Huber K, et al. 5-year outcomes after left atrial appendage closure: from the PREVAIL and PROTECT AF trials. J Am Coll Cardiol. 2017; 70:2964–75.
Search in Google Scholar Back to article
Tapaskar N, Pang A, Werner DA, Sengupta N. Resuming anticoagulation following hospitalization for gastrointestinal bleeding is associated with reduced thromboembolic events and improved mortality: results from a systematic review and meta-analysis. Dig Dis Sci. 2021; 66:554–66.
Search in Google Scholar Back to article
Murthy SB, Gupta A, Merkler AE, Navi BB, Mandava P, Iadecola C, et al. Restarting anticoagulant therapy after intracranial hemorrhage: a systematic review and meta-analysis. Stroke. 2017; 48:1594–600.
Search in Google Scholar Back to article
Giustozzi M, Proietti G, Becattini C, Roila F, Agnelli G, Mandalà M. ICH in primary or metastatic brain cancer patients with or without anticoagulant treatment: a systematic review and meta-analysis. Blood Adv. 2022; 6:4873–83.
Search in Google Scholar Back to article
Duytschaever M, Demolder A, Phlips T, Sarkozy A, El Haddad M, Taghji P, et al. Pulmonary vein isolation with vs. without continued antiarrhythmic Drug trEatment in subjects with Recurrent Atrial Fibrillation (POWDER AF): results from a multicentre randomized trial. Eur Heart J. 2018; 39:1429–37.
Search in Google Scholar Back to article
Moschovitis G, Johnson LSB, Blum S, Aeschbacher S, De Perna ML, Pagnamenta A, et al. Heart rate and adverse outcomes in patients with prevalent atrial fibrillation. Open Heart. 2021; 8:e001606. doi: 10.1136/openhrt-2021-001606
Open DOI Search in Google Scholar Back to article
Kotecha D, Calvert M, Deeks JJ, Griffith M, Kirchhof P, Lip GY, et al. A review of rate control in atrial fibrillation, and the rationale and protocol for the RATE-AF trial. BMJ Open. 2017; 7:e015099. doi: 10.1136/bmjopen-2016-015099
Open DOI Search in Google Scholar Back to article
Van Gelder IC, Groenveld HF, Crijns HJ, Tuininga YS, Tijssen JG, Alings AM, et al. Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med. 2010; 362:1363–73.
Search in Google Scholar Back to article
Opolski G, Torbicki A, Kosior DA, Szulc M, Wozakowska-Kaplon B, Kolodziej P, et al. Rate control vs rhythm control in patients with nonvalvular persistent atrial fibrillation: the results of the Polish How to Treat Chronic Atrial Fibrillation (HOT CAFE) study. Chest. 2004; 126:476–86.
Search in Google Scholar Back to article
Al-Khatib SM, Allen LaPointe NM, Chatterjee R, Crowley MJ, Dupre ME, Kong DF, et al. Rate- and rhythm-control therapies in patients with atrial fibrillation: a systematic review. Ann Intern Med. 2014; 160:760–73.
Search in Google Scholar Back to article
Steinberg BA, Kim S, Thomas L, Fonarow GC, Gersh BJ, Holmqvist F, et al. Increased heart rate is associated with higher mortality in patients with atrial fibrillation (AF): results from the outcomes registry for better informed treatment of AF (ORBIT-AF). J Am Heart Assoc. 2015; 4:e002031. doi: 10.1161/JAHA.115.002031
Open DOI Search in Google Scholar Back to article
Docherty KF, Shen L, Castagno D, Petrie MC, Abraham WT, Böhm M, et al. Relationship between heart rate and outcomes in patients in sinus rhythm or atrial fibrillation with heart failure and reduced ejection fraction. Eur J Heart Fail. 2020; 22:528–38.
Search in Google Scholar Back to article
Hess PL, Sheng S, Matsouaka R, DeVore AD, Heidenreich PA, Yancy CW, et al. Strict versus lenient versus poor rate control among patients with atrial fibrillation and heart failure (from the Get With The Guidelines – Heart Failure Program). Am J Cardiol. 2020; 125:894–900.
Search in Google Scholar Back to article
Olshansky B, Rosenfeld LE, Warner AL, Solomon AJ, O’Neill G, Sharma A, et al. The atrial fibrillation follow-up investigation of rhythm management (AFFIRM) study: approaches to control rate in atrial fibrillation. J Am Coll Cardiol. 2004; 43:1201–8.
Search in Google Scholar Back to article
Ulimoen SR, Enger S, Carlson J, Platonov PG, Pripp AH, Abdelnoor M, et al. Comparison of four single-drug regimens on ventricular rate and arrhythmia-related symptoms in patients with permanent atrial fibrillation. Am J Cardiol. 2013; 111:225–30.
Search in Google Scholar Back to article
Tisdale JE, Padhi ID, Goldberg AD, Silverman NA, Webb CR, Higgins RS, et al. A randomized, double-blind comparison of intravenous diltiazem and digoxin for atrial fibrillation after coronary artery bypass surgery. Am Heart J. 1998; 135:739–47.
Search in Google Scholar Back to article
Khand AU, Rankin AC, Martin W, Taylor J, Gemmell I, Cleland JG. Carvedilol alone or in combination with digoxin for the management of atrial fibrillation in patients with heart failure? J Am Coll Cardiol. 2003; 42:1944–51.
Search in Google Scholar Back to article
Ziff OJ, Lane DA, Samra M, Griffith M, Kirchhof P, Lip GY, et al. Safety and efficacy of digoxin: systematic review and meta-analysis of observational and controlled trial data. BMJ. 2015; 351:h4451. doi: 10.1136/bmj.h4451
Open DOI Search in Google Scholar Back to article
Champsi A, Mitchell C, Tica O, Ziff OJ, Bunting KV, Mobley AR, et al. Digoxin in patients with heart failure and/or atrial fibrillation: a systematic review and meta-analysis of 5.9 million patient years of follow-up2023. doi: 10.2139/ssrn.4544769
Open DOI Search in Google Scholar Back to article
Kotecha D, Bunting KV, Gill SK, Mehta S, Stanbury M, Jones JC, et al. Effect of digoxin vs bisoprolol for heart rate control in atrial fibrillation on patient-reported quality of life: the RATE-AF randomized clinical trial. JAMA. 2020; 324:2497–508.
Search in Google Scholar Back to article
Davey MJ, Teubner D. A randomized controlled trial of magnesium sulfate, in addition to usual care, for rate control in atrial fibrillation. Ann Emerg Med. 2005; 45:347–53.
Search in Google Scholar Back to article
Nogic J, MacPherson M, Aldridge E, Sajeev JK, Roberts L, Lowman D, et al. Magnesium in the management of atrial fibrillation with rapid ventricular response. JACC Clin Electrophysiol. 2022; 8:800–2.
Search in Google Scholar Back to article
Ramesh T, Lee PYK, Mitta M, Allencherril J. Intravenous magnesium in the management of rapid atrial fibrillation: a systematic review and meta-analysis. J Cardiol. 2021; 78:375–81.
Search in Google Scholar Back to article
Lim KT, Davis MJ, Powell A, Arnolda L, Moulden K, Bulsara M, et al. Ablate and pace strategy for atrial fibrillation: long-term outcome of AIRCRAFT trial. Europace. 2007; 9:498–505.
Search in Google Scholar Back to article
Brignole M, Pokushalov E, Pentimalli F, Palmisano P, Chieffo E, Occhetta E, et al. A randomized controlled trial of atrioventricular junction ablation and cardiac resynchronization therapy in patients with permanent atrial fibrillation and narrow QRS. Eur Heart J. 2018; 39:3999–4008.
Search in Google Scholar Back to article
Brignole M, Pentimalli F, Palmisano P, Landolina M, Quartieri F, Occhetta E, et al. AV junction ablation and cardiac resynchronization for patients with permanent atrial fibrillation and narrow QRS: the APAF-CRT mortality trial. Eur Heart J. 2021; 42:4731–9.
Search in Google Scholar Back to article
Grönberg T, Nuotio I, Nikkinen M, Ylitalo A, Vasankari T, Hartikainen JE, et al. Arrhythmic complications after electrical cardioversion of acute atrial fibrillation: the FinCV study. Europace. 2013; 15:1432–5.
Search in Google Scholar Back to article
Bonora A, Turcato G, Franchi E, Taioli G, Dilda A, Zerman G, et al. Efficacy and safety in pharmacological cardioversion of recent-onset atrial fibrillation: a propensity score matching to compare amiodarone vs class IC antiarrhythmic drugs. Intern Emerg Med. 2017; 12:853–9.
Search in Google Scholar Back to article
Alboni P, Botto GL, Baldi N, Luzi M, Russo V, Gianfranchi L, et al. Outpatient treatment of recent-onset atrial fibrillation with the “pill-in-the-pocket” approach. N Engl J Med. 2004; 351:2384–91.
Search in Google Scholar Back to article
Bjerkelund CJ, Orning OM. The efficacy of anticoagulant therapy in preventing embolism related to D.C. electrical conversion of atrial fibrillation. Am J Cardiol. 1969; 23:208–16.
Search in Google Scholar Back to article
Steffel J, Collins R, Antz M, Cornu P, Desteghe L, Haeusler KG, et al. 2021 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Europace. 2021; 23:1612–76.
Search in Google Scholar Back to article
Pluymaekers NAHA, Dudink EAMP, Luermans JGLM, Meeder JG, Lenderink T, Widdershoven J, et al. Early or delayed cardioversion in recent-onset atrial fibrillation. N Engl J Med. 2019; 380:1499–508.
Search in Google Scholar Back to article
Singh BN, Connolly SJ, Crijns HJ, Roy D, Kowey PR, Capucci A, et al. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med. 2007; 357:987–99.
Search in Google Scholar Back to article
Piccini JP, Hasselblad V, Peterson, Washam JB, Califf RM, Kong DF. Comparative efficacy of dronedarone and amiodarone for the maintenance of sinus rhythm in patients with atrial fibrillation. J Am Coll Cardiol. 2009; 54:1089–95.
Search in Google Scholar Back to article
Rillig A, Magnussen C, Ozga AK, Suling A, Brandes A, Breithardt G, et al. Early rhythm control therapy in patients with atrial fibrillation and heart failure. Circulation. 2021; 144:845–58.
Search in Google Scholar Back to article
Sohns C, Fox H, Marrouche NF, Crijns HJGM, Costard-Jaeckle A, Bergau L, et al. Catheter ablation in end-stage heart failure with atrial fibrillation. N Engl J Med. 2023; 389:1380–9.
Search in Google Scholar Back to article
Hocini M, Sanders P, Deisenhofer I, Jaïs P, Hsu LF, Scavée C, et al. Reverse remodeling of sinus node function after catheter ablation of atrial fibrillation in patients with prolonged sinus pauses. Circulation. 2003; 108:1172–5.
Search in Google Scholar Back to article
Oral H, Pappone C, Chugh A, Good E, Bogun F, Pelosi F Jr, et al. Circumferential pulmonary-vein ablation for chronic atrial fibrillation. N Engl J Med. 2006; 354:934–41.
Search in Google Scholar Back to article
Hunter RJ, Berriman TJ, Diab I, Kamdar R, Richmond L, Baker V, et al. A randomized controlled trial of catheter ablation versus medical treatment of atrial fibrillation in heart failure (the CAMTAF trial). Circ Arrhythm Electrophysiol. 2014; 7:31–8.
Search in Google Scholar Back to article
Packer DL, Piccini JP, Monahan KH, Al-Khalidi HR, Silverstein AP, Noseworthy PA, et al. Ablation versus drug therapy for atrial fibrillation in heart failure: results from the CABANA trial. Circulation. 2021; 143:1377–90.
Search in Google Scholar Back to article
Sohns C, Zintl K, Zhao Y, Dagher L, Andresen D, Siebels J, et al. Impact of left ventricular function and heart failure symptoms on outcomes post ablation of atrial fibrillation in heart failure: CASTLE-AF trial. Circ Arrhythm Electrophysiol. 2020; 13:e008461. doi: 10.1161/CIRCEP.120.008461
Open DOI Search in Google Scholar Back to article
Ishiguchi H, Yoshiga Y, Shimizu A, Ueyama T, Fukuda M, Kato T, et al. Long-term events following catheter-ablation for atrial fibrillation in heart failure with preserved ejection fraction. ESC Heart Fail. 2022; 9:3505–18.
Search in Google Scholar Back to article
Deshmukh A, Patel NJ, Pant S, Shah N, Chothani A, Mehta K, et al. In-hospital complications associated with catheter ablation of atrial fibrillation in the United States between 2000 and 2010: analysis of 93 801 procedures. Circulation. 2013; 128:2104–12.
Search in Google Scholar Back to article
Rizas KD, Freyer L, Sappler N, von Stülpnagel L, Spielbichler P, Krasniqi A, et al. Smartphone-based screening for atrial fibrillation: a pragmatic randomized clinical trial. Nat Med. 2022; 28:1823–30.
Search in Google Scholar Back to article
Leong-Sit P, Roux JF, Zado E, Callans DJ, Garcia F, Lin D, et al. Antiarrhythmics after ablation of atrial fibrillation (5A study): six-month follow-up study. Circ Arrhythm Electrophysiol. 2011; 4:11–4.
Search in Google Scholar Back to article
Zhou L, He L, Wang W, Li C, Li S, Tang R, et al. Effect of repeat catheter ablation vs. antiarrhythmic drug therapy among patients with recurrent atrial tachycardia/atrial fibrillation after atrial fibrillation catheter ablation: data from CHINA-AF registry. Europace. 2023; 25:382–9.
Search in Google Scholar Back to article
Sticherling C, Marin F, Birnie D, Boriani G, Calkins H, Dan GA, et al. Antithrombotic management in patients undergoing electrophysiological procedures: a European Heart Rhythm Association (EHRA) position document endorsed by the ESC Working Group Thrombosis, Heart Rhythm Society (HRS), and Asia Pacific Heart Rhythm Society (APHRS). Europace. 2015; 17:1197–214.
Search in Google Scholar Back to article
Lurie A, Wang J, Hinnegan KJ, McIntyre WF, Belley-Côté EP, Amit G, et al. Prevalence of left atrial thrombus in anticoagulated patients with atrial fibrillation. J Am Coll Cardiol. 2021; 77:2875–86.
Search in Google Scholar Back to article
van Vugt SPG, Westra SW, Volleberg RHJA, Hannink G, Nakamura R, de Asmundis C, et al. Meta-analysis of controlled studies on minimally interrupted vs. continuous use of non-vitamin K antagonist oral anticoagulants in catheter ablation for atrial fibrillation. Europace. 2021; 23:1961–9.
Search in Google Scholar Back to article
Calkins H, Hindricks G, Cappato R, Kim YH, Saad EB, Aguinaga L, et al. 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation: executive summary. Europace. 2018; 20:157–208.
Search in Google Scholar Back to article
Pathak RK, Middeldorp ME, Lau DH, Mehta AB, Mahajan R, Twomey D, et al. Aggressive risk factor reduction study for atrial fibrillation and implications for the outcome of ablation: the ARREST-AF cohort study. J Am Coll Cardiol. 2014; 64:2222–31.
Search in Google Scholar Back to article
Wong CX, Sullivan T, Sun MT, Mahajan R, Pathak RK, Middeldorp M, et al. Obesity and the risk of incident, post-operative, and post-ablation atrial fibrillation: a meta-analysis of 626,603 individuals in 51 studies. JACC Clin Electrophysiol. 2015; 1:139–52.
Search in Google Scholar Back to article
Abed HS, Wittert GA, Leong DP, Shirazi MG, Bahrami B, Middeldorp ME, et al. Effect of weight reduction and cardiometabolic risk factor management on symptom burden and severity in patients with atrial fibrillation: a randomized clinical trial. JAMA. 2013; 310:2050–60.
Search in Google Scholar Back to article
Middeldorp ME, Pathak RK, Meredith M, Mehta AB, Elliott AD, Mahajan R, et al. PREVEntion and regReSsive Effect of weight-loss and risk factor modification on atrial fibrillation: the REVERSE-AF study. Europace. 2018; 20:1929–35.
Search in Google Scholar Back to article
Donnellan E, Wazni O, Kanj M, Hussein A, Baranowski B, Lindsay B, et al. Outcomes of atrial fibrillation ablation in morbidly obese patients following bariatric surgery compared with a nonobese cohort. Circ Arrhythm Electrophysiol. 2019; 12:e007598. doi: 10.1161/CIRCEP.119.007598
Open DOI Search in Google Scholar Back to article
Mahajan R, Lau DH, Brooks AG, Shipp NJ, Wood JPM, Manavis J, et al. Atrial fibrillation and obesity: reverse remodeling of atrial substrate with weight reduction. JACC Clin Electrophysiol. 2021; 7:630–41.
Search in Google Scholar Back to article
Kadhim K, Middeldorp ME, Elliott AD, Agbaedeng T, Gallagher C, Malik V, et al. Prevalence and assessment of sleep-disordered breathing in patients with atrial fibrillation: a systematic review and meta-analysis. Can J Cardiol. 2021; 37:1846–56.
Search in Google Scholar Back to article
Li L, Wang ZW, Li J, Ge X, Guo LZ, Wang Y, et al. Efficacy of catheter ablation of atrial fibrillation in patients with obstructive sleep apnoea with and without continuous positive airway pressure treatment: a meta-analysis of observational studies. Europace. 2014; 16:1309–14.
Search in Google Scholar Back to article
Nalliah CJ, Wong GR, Lee G, Voskoboinik A, Kee K, Goldin J, et al. Impact of CPAP on the atrial fibrillation substrate in obstructive sleep apnea: the SLEEP-AF study. JACC Clin Electrophysiol. 2022; 8:869–77.
Search in Google Scholar Back to article
Hunt TE, Traaen GM, Aakerøy L, Bendz C, Øverland B, Akre H, et al. Effect of continuous positive airway pressure therapy on recurrence of atrial fibrillation after pulmonary vein isolation in patients with obstructive sleep apnea: a randomized controlled trial. Heart Rhythm. 2022; 19:1433–41.
Search in Google Scholar Back to article
Elliott AD, Linz D, Mishima R, Kadhim K, Gallagher C, Middeldorp ME, et al. Association between physical activity and risk of incident arrhythmias in 402 406 individuals: evidence from the UK Biobank cohort. Eur Heart J. 2020; 41:1479–86.
Search in Google Scholar Back to article
Elliott AD, Maatman B, Emery MS, Sanders P. The role of exercise in atrial fibrillation prevention and promotion: finding optimal ranges for health. Heart Rhythm. 2017; 14:1713–20.
Search in Google Scholar Back to article
Malmo V, Nes BM, Amundsen BH, Tjonna AE, Stoylen A, Rossvoll O, et al. Aerobic interval training reduces the burden of atrial fibrillation in the short term: a randomized trial. Circulation. 2016; 133:466–73.
Search in Google Scholar Back to article
126. Elliott AD, Verdicchio CV, Mahajan R, Middeldorp ME, Gallagher C, Mishima RS, et al. An exercise and physical activity program in patients with atrial fibrillation: the ACTIVE-AF randomized controlled trial. JACC Clin Electrophysiol. 2023; 9:455–65.
Search in Google Scholar Back to article
Kodama S, Saito K, Tanaka S, Horikawa C, Saito A, Heianza Y, et al. Alcohol consumption and risk of atrial fibrillation: a meta-analysis. J Am Coll Cardiol. 2011; 57:427–36.
Search in Google Scholar Back to article
Voskoboinik A, Wong G, Lee G, Nalliah C, Hawson J, Prabhu S, et al. Moderate alcohol consumption is associated with atrial electrical and structural changes: insights from high-density left atrial electroanatomic mapping. Heart Rhythm. 2019; 16:251–9.
Search in Google Scholar Back to article
Voskoboinik A, Costello BT, Kalman E, Prabhu S, Sugumar H, Wong G, et al. Regular alcohol consumption is associated with impaired atrial mechanical function in the atrial fibrillation population: a cross-sectional MRI-based study. JACC Clin Electrophysiol. 2018; 4:1451–9.
Search in Google Scholar Back to article
Voskoboinik A, Kalman JM, De Silva A, Nicholls T, Costello B, Nanayakkara S, et al. Alcohol abstinence in drinkers with atrial fibrillation. N Engl J Med. 2020; 382:20–8.
Search in Google Scholar Back to article
Karayiannides S, Norhammar A, Landstedt-Hallin L, Friberg L, Lundman P. Prognostic impact of type 1 and type 2 diabetes mellitus in atrial fibrillation and the effect of severe hypoglycaemia: a nationwide cohort study. Eur J Prev Cardiol. 2022; 29:1759–69.
Search in Google Scholar Back to article
Anselmino M, Matta M, D’ascenzo F, Pappone C, Santinelli V, Bunch TJ, et al. Catheter ablation of atrial fibrillation in patients with diabetes mellitus: a systematic review and meta-analysis. Europace. 2015; 17:1518–25.
Search in Google Scholar Back to article
Donnellan E, Aagaard P, Kanj M, Jaber W, Elshazly M, Hoosien M, et al. Association between pre-ablation glycemic control and outcomes among patients with diabetes undergoing atrial fibrillation ablation. JACC Clin Electrophysiol. 2019; 5:897–903.
Search in Google Scholar Back to article
Pandey AK, Okaj I, Kaur H, Belley-Cote EP, Wang J, Oraii A, et al. Sodium-glucose co-transporter inhibitors and atrial fibrillation: a systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc. 2021; 10:e022222. doi: 10.1161/JAHA.121.022222
Open DOI Search in Google Scholar Back to article
Filippatos G, Bakris GL, Pitt B, Agarwal R, Rossing P, Ruilope LM, et al. Finerenone reduces new-onset atrial fibrillation in patients with chronic kidney disease and type 2 diabetes. J Am Coll Cardiol. 2021; 78:142–52.
Search in Google Scholar Back to article
Kim TH, Yang PS, Yu HT, Jang E, Shin H, Kim HY, et al. Effect of hypertension duration and blood pressure level on ischaemic stroke risk in atrial fibrillation: nationwide data covering the entire Korean population. Eur Heart J. 2019; 40:809–19.
Search in Google Scholar Back to article
Pinho-Gomes AC, Azevedo L, Copland E, Canoy D, Nazarzadeh M, Ramakrishnan R, et al. Blood pressure-lowering treatment for the prevention of cardiovascular events in patients with atrial fibrillation: an individual participant data meta-analysis. PLoS Med. 2021; 18:e1003599. doi: 10.1371/journal.pmed.1003599
Open DOI Search in Google Scholar Back to article
Parkash R, Wells GA, Sapp JL, Healey JS, Tardif JC, Greiss I, et al. Effect of aggressive blood pressure control on the recurrence of atrial fibrillation after catheter ablation: a randomized, open-label clinical trial (SMAC-AF [substrate modification with aggressive blood pressure control]). Circulation. 2017; 135:1788–98.
Search in Google Scholar Back to article
Santhanakrishnan R, Wang N, Larson MG, Magnani JW, McManus DD, Lubitz SA, et al. Atrial fibrillation begets heart failure and vice versa: temporal associations and differences in preserved versus reduced ejection fraction. Circulation. 2016; 133:484–92.
Search in Google Scholar Back to article
Rienstra M, Hobbelt AH, Alings M, Tijssen JGP, Smit MD, Brügemann J, et al. Targeted therapy of underlying conditions improves sinus rhythm maintenance in patients with persistent atrial fibrillation: results of the RACE 3 trial. Eur Heart J. 2018; 39:2987–96.
Search in Google Scholar Back to article
Pelliccia A, Sharma S, Gati S, Bäck M, Börjesson M, Caselli S, et al. 2020 ESC guidelines on sports cardiology and exercise in patients with cardiovascular disease. Eur Heart J. 2021; 42:17–96.
Search in Google Scholar Back to article
Pérez FJ, Schubert CM, Parvez B, Pathak V, Ellenbogen KA, Wood MA. Long-term outcomes after catheter ablation of cavo-tricuspid isthmus dependent atrial flutter: a meta-analysis. Circ Arrhythm Electrophysiol. 2009; 2:393–401.
Search in Google Scholar Back to article
Mandsager KT, Phelan DM, Diab M, Baranowski B, Saliba WI, Tarakji KG, et al. Outcomes of pulmonary vein isolation in athletes. JACC Clin Electrophysiol. 2020; 6:1265–74.
Search in Google Scholar Back to article
Zipes DP, Link MS, Ackerman MJ, Kovacs RJ, Myerburg RJ, Estes NAM 3rd. Eligibility and disqualification recommendations for competitive athletes with cardiovascular abnormalities: Task Force 9: arrhythmias and conduction defects: a scientific statement from the American Heart Association and American College of Cardiology. J Am Coll Cardiol. 2015; 66:2412–23.
Search in Google Scholar Back to article
Benali K, Macle L, Haïssaguerre M, Kneizeh K, Vlachos K, Yokoyama M, et al. Catheter ablation of paroxysmal atrial fibrillation and disease progression: magnitude of the antiprogression effect and role of intervention timing. Heart Rhythm. 2025; 22:e23–e29. doi: 10.1016/j.hrthm.2024.12.026
Open DOI Search in Google Scholar Back to article
Kawabata M, Hirao K, Horikawa T, Suzuki K, Motokawa K, Suzuki F, et al. Syncope in patients with atrial flutter during treatment with class Ic antiarrhythmic drugs. J Electrocardiol. 2001; 34:65–72.
Search in Google Scholar Back to article
Darby AE, Dimarco JP. Management of atrial fibrillation in patients with structural heart disease. Circulation. 2012; 125:945–57.
Search in Google Scholar Back to article
Phaisitkriengkrai A, Methavigul K, Hengrussamee K. Clinical outcomes of AF patients with non-rheumatic valvular heart disease in Thailand. J Med Serv. 2020; 45:29–34.
Search in Google Scholar Back to article
Luengsupabul S, Methavigul K, Methavigul R. Optimal INR level in patients with atrial fibrillation with EHRA type 2 valvular heart disease receiving warfarin. J Arrhythm. 2020; 36:425–9.
Search in Google Scholar Back to article
Renda G, Ricci F, Giugliano RP, De Caterina R. Non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and valvular heart disease. J Am Coll Cardiol. 2017; 69:1363–71.
Search in Google Scholar Back to article
Thomas KL, Jackson LR 2nd, Shrader P, Ansell J, Fonarow GC, Gersh B, et al. Prevalence, characteristics, and outcomes of valvular heart disease in patients with atrial fibrillation: insights from the ORBIT-AF (Outcomes Registry for Better Informed Treatment for Atrial Fibrillation). J Am Heart Assoc. 2017; 6:e006475. doi: 10.1161/JAHA.117.006475
Open DOI Search in Google Scholar Back to article
Krittayaphong R, Boonyapiphat T, Wongvipaporn C, Sairat P, Investigators C-A. Age-related clinical outcomes of patients with non-valvular atrial fibrillation: insights from the COOL-AF registry. Clin Interv Aging. 2021; 16:707–19.
Search in Google Scholar Back to article
Methavigul K, Boonyapisit W. Optimal INR level in Thai atrial fibrillation patients who were receiving warfarin for stroke prevention in Thailand. J Med Assoc Thai. 2014; 97:1274–80.
Search in Google Scholar Back to article
Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014; 383:955–62.
Search in Google Scholar Back to article
Patti G, Pecen L, Lucerna M, Huber K, Rohla M, Renda G, et al. Net clinical benefit of non-vitamin K antagonist vs vitamin K antagonist anticoagulants in elderly patients with atrial fibrillation. Am J Med. 2019; 132:749–57.e745. doi: 10.1016/j.amjmed.2018.12.036
Open DOI Search in Google Scholar Back to article
Joosten LPT, van Doorn S, van de Ven PM, Köhlen BTG, Nierman MC, Koek HL, et al. Safety of switching from a vitamin K antagonist to a non-vitamin K antagonist oral anticoagulant in frail older patients with atrial fibrillation: results of the FRAIL-AF randomized controlled trial. Circulation. 2024; 149:279–89.
Search in Google Scholar Back to article
Pietersen AH, Andersen ED, Sandøe E. Atrial fibrillation in the Wolff–Parkinson–White syndrome. Am J Cardiol. 1992; 70:38A–43A. doi: 10.1016/0002-9149(92)91076-G
Open DOI Search in Google Scholar Back to article
Roth A, Elkayam I, Shapira I, Sander J, Malov N, Kehati M, et al. Effectiveness of prehospital synchronous direct-current cardioversion for supraventricular tachyarrhythmias causing unstable hemodynamic states. Am J Cardiol. 2003; 91:489–91.
Search in Google Scholar Back to article
Sellers TD Jr, Campbell RW, Bashore TM, Gallagher JJ. Effects of procainamide and quinidine sulfate in the Wolff–Parkinson–White syndrome. Circulation. 1977; 55:15–22.
Search in Google Scholar Back to article
Glatter KA, Dorostkar PC, Yang Y, Lee RJ, Van Hare GF, Keung E, et al. Electrophysiological effects of ibutilide in patients with accessory pathways. Circulation. 2001; 104:1933–9.
Search in Google Scholar Back to article
Boriani G, Biffi M, Frabetti L, Azzolini U, Sabbatani P, Bronzetti G, et al. Ventricular fibrillation after intravenous amiodarone in Wolff–Parkinson–White syndrome with atrial fibrillation. Am Heart J. 1996; 131:1214–6.
Search in Google Scholar Back to article
Kim RJ, Gerling BR, Kono AT, Greenberg ML. Precipitation of ventricular fibrillation by intravenous diltiazem and metoprolol in a young patient with occult Wolff–Parkinson–White syndrome. Pacing Clin Electrophysiol. 2008; 31:776–9.
Search in Google Scholar Back to article
Sellers TD Jr, Bashore TM, Gallagher JJ. Digitalis in the pre-excitation syndrome. Analysis during atrial fibrillation. Circulation. 1977; 56:260–7.
Search in Google Scholar Back to article
Gulamhusein S, Ko P, Carruthers SG, Klein GJ. Acceleration of the ventricular response during atrial fibrillation in the Wolff–Parkinson–White syndrome after verapamil. Circulation. 1982; 65:348–54.
Search in Google Scholar Back to article
Klein I, Ojamaa K. Thyroid hormone and the cardiovascular system. N Engl J Med. 2001; 344:501–9.
Search in Google Scholar Back to article
Nilsson OR, Karlberg BE, Kågedal B, Tegler L, Almqvist S. Non-selective and selective beta-1-adrenoceptor blocking agents in the treatment of hyperthyroidism. Acta Med Scand. 1979; 206:21–5.
Search in Google Scholar Back to article
Nakazawa HK, Sakurai K, Hamada N, Momotani N, Ito K. Management of atrial fibrillation in the post-thyrotoxic state. Am J Med. 1982; 72:903–6.
Search in Google Scholar Back to article
Tng EL, Tiong YS, Aung AT, Chong NYY, Wang Z. Efficacy and safety of anticoagulation in thyrotoxic atrial fibrillation: a systematic review and meta-analysis. Endocr Connect. 2022; 11:e220166. doi: 10.1530/EC-22-0166
Open DOI Search in Google Scholar Back to article
Writing Committee Members, Joglar JA, Chung MK, Armbruster AL, Benjamin EJ, Chyou JY, et al. 2023 ACC/AHA/ACCP/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2024; 83:109–279.
Search in Google Scholar Back to article
McDevitt DG, Nelson JK. Comparative trial of atenolol and propranolol in hyperthyroidism. Br J Clin Pharmacol. 1978; 6:233–7.
Search in Google Scholar Back to article
Tagami T, Yambe Y, Tanaka T, Tanaka T, Ogo A, Yoshizumi H, et al. Short-term effects of ß-adrenergic antagonists and methimazole in new-onset thyrotoxicosis caused by Graves’ disease. Intern Med. 2012; 51:2285–90.
Search in Google Scholar Back to article
Petersen P, Hansen JM. Stroke in thyrotoxicosis with atrial fibrillation. Stroke. 1988; 19:15–8.
Search in Google Scholar Back to article
Gundlund A, Kümler T, Bonde AN, Butt JH, Gislason GH, Torp-Pedersen C, et al. Comparative thromboembolic risk in atrial fibrillation with and without a secondary precipitant—Danish nationwide cohort study. BMJ Open. 2019; 9:e028468. doi: 10.1136/bmjopen-2018-028468
Open DOI Search in Google Scholar Back to article
González-Pacheco H, Márquez MF, Arias-Mendoza A, Álvarez-Sangabriel A, Eid-Lidt G, González-Hermosillo A, et al. Clinical features and in-hospital mortality associated with different types of atrial fibrillation in patients with acute coronary syndrome with and without ST elevation. J Cardiol. 2015; 66:148–54.
Search in Google Scholar Back to article
Guimarães PO, Zakroysky P, Goyal A, Lopes RD, Kaltenbach LA, Wang TY. Usefulness of antithrombotic therapy in patients with atrial fibrillation and acute myocardial infarction. Am J Cardiol. 2019; 123:12–8.
Search in Google Scholar Back to article
Kurlander JE, Barnes GD, Fisher A, Gonzalez JJ, Helminski D, Saini SD, et al. Association of antisecretory drugs with upper gastrointestinal bleeding in patients using oral anticoagulants: a systematic review and meta-analysis. Am J Med. 2022; 135:1231–1243.e8. doi: 10.1016/j. amjmed.2022.05.031
Open DOI Search in Google Scholar Back to article
Vaidya VR, Arora S, Patel N, Badheka AO, Patel N, Agnihotri K, et al. Burden of arrhythmia in pregnancy. Circulation. 2017; 135:619–21.
Search in Google Scholar Back to article
Hoeltzenbein M, Beck E, Meixner K, Schaefer C, Kreutz R. Pregnancy outcome after exposure to the novel oral anticoagulant rivaroxaban in women at suspected risk for thromboembolic events: a case series from the German Embryotox Pharmacovigilance Centre. Clin Res Cardiol. 2016; 105:117–26.
Search in Google Scholar Back to article
Bedford JP, Ferrando-Vivas P, Redfern O, Rajappan K, Harrison DA, Watkinson PJ, et al. New-onset atrial fibrillation in intensive care: epidemiology and outcomes. Eur Heart J Acute Cardiovasc Care. 2022; 11:620–8.
Search in Google Scholar Back to article
McIntyre WF, Um KJ, Cheung CC, Belley-Côté EP, Dingwall O, Devereaux PJ, et al. Atrial fibrillation detected initially during acute medical illness: a systematic review. Eur Heart J Acute Cardiovasc Care. 2019; 8:130–41.
Search in Google Scholar Back to article
Gillinov AM, Bagiella E, Moskowitz AJ, Raiten JM, Groh MA, Bowdish ME, et al. Rate control versus rhythm control for atrial fibrillation after cardiac surgery. N Engl J Med. 2016; 374:1911–21.
Search in Google Scholar Back to article
Rezk M, Taha A, Nielsen SJ, Gudbjartsson T, Bergfeldt L, Ahlsson A, et al. Clinical course of postoperative atrial fibrillation after cardiac surgery and long-term outcome. Ann Thorac Surg. 2022; 114:2209–15.
Search in Google Scholar Back to article
Gaudino M, Di Franco A, Rong LQ, Piccini J, Mack M. Postoperative atrial fibrillation: from mechanisms to treatment. Eur Heart J. 2023; 44:1020–39.
Search in Google Scholar Back to article
Kotecha D, Castella M. Is it time to treat post-operative atrial fibrillation just like regular atrial fibrillation? Eur Heart J. 2020; 41:652–654a. doi: 10.1093/eurheartj/ehz412
Open DOI Search in Google Scholar Back to article
Lee SH, Kang DR, Uhm JS, Shim J, Sung JH, Kim JY, et al. New-onset atrial fibrillation predicts long-term newly developed atrial fibrillation after coronary artery bypass graft. Am Heart J. 2014; 167:593–600.e1. doi: 10.1016/j.ahj.2013.12.010
Open DOI Search in Google Scholar Back to article
Eikelboom R, Sanjanwala R, Le ML, Yamashita MH, Arora RC. Postoperative atrial fibrillation after cardiac surgery: a systematic review and meta-analysis. Ann Thorac Surg. 2021; 111:544–54.
Search in Google Scholar Back to article
Auer J, Weber T, Berent R, Puschmann R, Hartl P, Ng CK, et al. A comparison between oral antiarrhythmic drugs in the prevention of atrial fibrillation after cardiac surgery: the pilot study of prevention of postoperative atrial fibrillation (SPPAF), a randomized, placebocontrolled trial. Am Heart J. 2004; 147:636–43.
Search in Google Scholar Back to article
Crystal E, Garfinkle MS, Connolly SS, Ginger TT, Sleik K, Yusuf SS. Interventions for preventing post-operative atrial fibrillation in patients undergoing heart surgery. Cochrane Database Syst Rev. 2013; 2013:CD003611. doi: 10.1002/14651858.CD003611.pub3
Open DOI Search in Google Scholar Back to article
Zhang L, Gao S. Systematic review and meta-analysis of atrial fibrillation prophylaxis after lung surgery. J Cardiovasc Pharmacol. 2016; 67:351–7.
Search in Google Scholar Back to article
Riber LP, Larsen TB, Christensen TD. Postoperative atrial fibrillation prophylaxis after lung surgery: systematic review and meta-analysis. Ann Thorac Surg. 2014; 98:1989–97.
Search in Google Scholar Back to article
Ziff OJ, Samra M, Howard JP, Bromage DI, Ruschitzka F, Francis DP, et al. Beta-blocker efficacy across different cardiovascular indications: an umbrella review and meta-analytic assessment. BMC Med. 2020; 18:103. doi: 10.1186/s12916-020-01564-3
Open DOI Search in Google Scholar Back to article
Taha A, Nielsen SJ, Bergfeldt L, Ahlsson A, Friberg L, Björck S, et al. New-onset atrial fibrillation after coronary artery bypass grafting and long-term outcome: a population-based nationwide study from the SWEDEHEART registry. J Am Heart Assoc. 2021; 10:e017966. doi: 10.1161/JAHA.120.017966
Open DOI Search in Google Scholar Back to article
O’Brien B, Burrage PS, Ngai JY, Prutkin JM, Huang CC, Xu X, et al. Society of cardiovascular anesthesiologists/European association of cardiothoracic anaesthetists practice advisory for the management of perioperative atrial fibrillation in patients undergoing cardiac surgery. J Cardiothorac Vasc Anesth. 2019; 33:12–26.
Search in Google Scholar Back to article
Neves IA, Magalhães A, Lima da Silva G, Almeida AG, Borges M, Costa J, et al. Anticoagulation therapy in patients with post-operative atrial fibrillation: systematic review with meta-analysis. Vascul Pharmacol. 2022; 142:106929. doi: 10.1016/j.vph.2021.106929
Open DOI Search in Google Scholar Back to article
Yun JP, Choi EK, Han KD, Park SH, Jung JH, Park SH, et al. Risk of atrial fibrillation according to cancer type: a nationwide population-based study. JACC CardioOncol. 2021; 3:221–32.
Search in Google Scholar Back to article
Alexandre J, Salem JE, Moslehi J, Sassier M, Ropert C, Cautela J, et al. Identification of anticancer drugs associated with atrial fibrillation: analysis of the WHO pharmacovigilance database. Eur Heart J Cardiovasc Pharmacother. 2021; 7:312–20.
Search in Google Scholar Back to article
Buza V, Rajagopalan B, Curtis AB. Cancer treatment-induced arrhythmias: focus on chemotherapy and targeted therapies. Circ Arrhythm Electrophysiol. 2017; 10:e005443. doi: 10.1161/CIRCEP.117.005443
Open DOI Search in Google Scholar Back to article
Bansal N, Fan D, Hsu CY, Ordonez JD, Marcus GM, Go AS. Incident atrial fibrillation and risk of end-stage renal disease in adults with chronic kidney disease. Circulation. 2013; 127:569–74.
Search in Google Scholar Back to article
Lin YC, Chen BL, Shih CM, Lin FY, Chen CW, Hsu CY, et al. Effectiveness and safety of rivaroxaban versus warfarin in Taiwanese patients with end-stage renal disease and nonvalvular atrial fibrillation: a real-world nationwide cohort study. PLoS One. 2021; 16:e0249940. doi: 10.1371/journal.pone.0249940
Open DOI Search in Google Scholar Back to article
Reinecke H, Engelbertz C, Bauersachs R, Breithardt G, Echterhoff HH, Gerß J, et al. A randomized controlled trial comparing apixaban with the vitamin K antagonist phenprocoumon in patients on chronic hemodialysis: the AXADIA-AFNET 8 study. Circulation. 2023; 147:296–309.
Search in Google Scholar Back to article
Genovesi S, Porcu L, Slaviero G, Casu G, Bertoli S, Sagone A, et al. Outcomes on safety and efficacy of left atrial appendage occlusion in end stage renal disease patients undergoing dialysis. J Nephrol. 2021; 34:63–73.
Search in Google Scholar Back to article
Suri C, Pande B, Sahu T, Sahithi LS, Verma HK. Anticoagulation in atrial fibrillation and liver disease: a pooled-analysis of >20,000 patients. Eur Heart J Cardiovasc Pharmacother. 2022; 8:336–45.
Search in Google Scholar Back to article